MedReview announced it has acquired Vital Data Technology, strengthening its suite of solutions for healthcare payers by adding advanced analytics and member outcome-focused capabilities.
Vital Data Technology, founded in 2005, provides AI-driven analytics through its Affinitē platform, enabling health plans to make faster, data-informed decisions across care management, quality improvement, population health, and risk adjustment. The acquisition enhances MedReview’s ability to deliver more comprehensive solutions aimed at improving patient outcomes while reducing costs.
The combined organization will integrate Vital Data’s predictive insights and workflow technology into MedReview’s existing payment integrity offerings, which include pre-pay and post-pay reviews, audits, and data mining services. Vital Data will operate as a wholly owned subsidiary of MedReview.
The financial terms of the transaction were not disclosed. Advisors on the deal included Synergy Advisors and Goodwin for MedReview, and Bailey & Company and Sheppard for Vital Data Technology.
KEY QUOTES:
“This acquisition represents an important step forward in our long term strategy. By bringing these two organizations together, we strengthen our collective ability to deliver greater value to the clients of both organizations while expanding our capabilities in ways that position us well for the future. We are excited about the opportunities ahead and about welcoming an exceptional team into our organization.”
Spencer Young, CEO of MedReview
“We’re pleased to find a complementary business partner who shares our commitment to increasing the quality of care, successful patient outcomes, and measurable waste reduction. Joining forces with MedReview advances Vital Data’s ability to achieve our mission and enable payers to act with confidence.”
Matt D’Ambrosia, CEO of Vital Data Technology
“The addition of Vital Data’s technology and talent to the MedReview family is rooted in a shared vision for innovation and delivering greater value to our healthcare payer partners.”
Gail Donovan, Chairperson of the Board for MedReview
